Addressing the Spectrum of Spinal Ependymoma

Addressing the Spectrum of Spinal Ependymoma

The Pediatric Special Interest Track of the Society for Neuro-Oncology is pleased to present the Pediatric Tumor Board “Pediatric SNO-Storm: A Collaborative Brainstorm Addressing Challenging Pediatric CNS Tumors from Around the World” quarterly webinar. Registration is free and limited to the first 1,000 participants. All SNO webinars are recorded, so if you miss one, you will be able to view it on-demand through the Neuro-Oncology Academy. 

Please email academy@soc-neuro-onc.org for technical issues. 

Target Audience

Program Overview

With the release of the 2021 WHO CNS tumor classifications, classification of primary spinal ependymoma changed to better align with newly defined molecular subgroups. Ependymomas arising in the spine have been recognized to harbor key characteristics and epidemiology that better predict clinical outcome than histology/morphology alone. In this webinar, we intend to summarize the classifications of myxopapillary ependymoma (MPE), spinal ependymoma (SP-EPN), and spinal ependymoma MYCN-amplified (SP-MYCN), and as well as neurofibromatosis 2 (NF-2)-associated spinal ependymoma, to highlight clinical implications, treatment avenues, and future directions for targeted therapy.

Learning Objectives

• Review the 2021 WHO CNS tumor classification of spinal ependymoma, including the impact of changes to molecularly defined subgroups and grading
• Review key molecular and clinical characteristics of primary spinal ependymomas and their treatment approaches
• Discuss the role of tumor predisposition testing in primary spinal ependymoma